Swiss Multiple Sclerosis Cohort-Study

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Apr 28, 2015

Keywords

ClinConnect Summary

The Swiss Multiple Sclerosis Cohort Study (SMSC) is a research project aimed at better understanding multiple sclerosis (MS) and related conditions, like neuromyelitis optica spectrum disorder (NMOSD) and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The study is taking place across eight centers in Switzerland and seeks to follow a group of patients for a long time—possibly many years. Researchers will collect important information about participants' health, including regular check-ups and MRI scans, to learn more about how these diseases progress and how treatments work. They hope to find better ways to predict how a patient's disease will evolve and the effectiveness and safety of different therapies.

To participate, individuals need to have a confirmed diagnosis of one of the specified conditions and be willing to visit the hospital every six or twelve months for check-ups and blood tests. The study welcomes all genders and has no specific age limit. By joining, participants will help researchers gather valuable data that could improve treatment options for MS and related disorders, ultimately benefiting many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fulfilling the diagnosis of radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting Multiple Sclerosis (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), neuromyelitis optica spectrum disorder (NMOSD) or Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) according to established criteria
• • Intending to attend hospital visits every 6 months (+/- 45 days) or 12 months (+/- 45 days) (facultative cranial MRI every 12 months) over a longer period (at least 5 years)
• • Intending to give blood for biobanking every 6 or 12 months during hospital visit or as close as possible to the visit (+/- 8 days)
• • Inclusion criteria are crafted to identify a population of patients with MS, NMOSD or MOGAD particularly suitable for analysing disease evolution and associated factors, treatment dynamics, and the long-term safety and efficacy profile of disease-modifying drugs.
• • There are no specific Exclusion Criteria.